Roche, Genentech and Merck Tipped for Strong Growth in Cancer Markets Says Report from URCH Publishing
Some Big Pharma Will See Declining Cancer Sales Notes URCH Publishing
LONDON--(BUSINESS WIRE)--Just three of 2007's top companies producing cancer medicines are forecast to significantly grow their sales in the oncology segment over the next five years, says a new market research report from URCH Publishing.
Of these top ten companies, only Roche, Genentech and Merck are tipped to grow sales of their cancer portfolio by double-digit annual growth rates says, "Cancer Market Trends 2008 - 2012: Key market forecasts and growth opportunities". In contrast, Sanofi-Aventis, AstraZeneca and J&J are forecast to suffer declining cancer sales over the next five years.
Commenting on the findings, Steve Seget, author of the report, said: "Roche is forecast to overtake Amgen to become the leading company by cancer sales in 2012." Other changes will include Genentech passing Novartis to become the third leading cancer company, while Merck will overtake Eli Lilly, Pfizer, AstraZeneca and Sanofi-Aventis to become the sixth leading cancer company in 2012.
Only five of the top 10 cancer products in 2007 are forecast to increase sales over the next five years, notes the report. Amgen's Aranesp and Epogen, J&J's Eprex/Procrit and Sanofi-Aventis' Taxotere and Eloxatin are all forecast to suffer declining sales between 2007 and 2012.
A total of 14 pharmaceutical companies were identified as having generated cancer sales in excess of $1 billion in 2007.
The 120 page report forecasts that the global market for pharmaceutical cancer treatments will grow to $103.9 billion by 2012, equivalent to a CAGR of 9.4% over the next five years. The global market for new cancer patients is set to increase from 4 million cases in the major pharmaceutical markets in 2007 to 4.2 million in 2012.
URCH's comprehensive report delivers accurate market figures and forecasts on the global cancer drug market and contains profiles of top pharmaceutical companies in this sector.
"Cancer Market Trends 2008 - 2012 - Key market forecasts and growth opportunities" is available from URCH Publishing. Find more details at: http://www.urchpublishing.com/publications/therapeutic/cancer_market_trends.html
About URCH Publishing Ltd (http://www.urchpublishing.com)
URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry. For more information contact URCH Publishing on +44 (0) 20 7060 1099 or email firstname.lastname@example.org.